France · Delayed Price · Currency is EUR ABIONYX Pharma Statistics
Total Valuation
ABIONYX Pharma has a market cap or net worth of EUR 126.22 million. The enterprise value is 125.75 million.
| Market Cap | 126.22M |
| Enterprise Value | 125.75M |
Important Dates
The last earnings date was Thursday, September 25, 2025.
| Earnings Date | Sep 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABIONYX Pharma has 34.68 million shares outstanding.
| Current Share Class | 34.68M |
| Shares Outstanding | 34.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.62% |
| Owned by Institutions (%) | 4.73% |
| Float | 20.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.14 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.39 |
| EV / Sales | 29.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -35.88 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 84,922 |
| Profits Per Employee | -90,020 |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +182.17% in the last 52 weeks. The beta is 1.30, so ABIONYX Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +182.17% |
| 50-Day Moving Average | 2.62 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 55.36 |
| Average Volume (20 Days) | 586,211 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABIONYX Pharma had revenue of EUR 4.33 million and -4.59 million in losses.
| Revenue | 4.33M |
| Gross Profit | 774,000 |
| Operating Income | -4.67M |
| Pretax Income | -4.59M |
| Net Income | -4.59M |
| EBITDA | -4.55M |
| EBIT | -4.67M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was -3.46 million and capital expenditures -45,000, giving a free cash flow of -3.51 million.
| Operating Cash Flow | -3.46M |
| Capital Expenditures | -45,000 |
| Free Cash Flow | -3.51M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 17.87%, with operating and profit margins of -107.71% and -106.00%.
| Gross Margin | 17.87% |
| Operating Margin | -107.71% |
| Pretax Margin | -106.00% |
| Profit Margin | -106.00% |
| EBITDA Margin | -105.07% |
| EBIT Margin | -107.71% |
| FCF Margin | n/a |
Dividends & Yields
ABIONYX Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.64% |
| FCF Yield | -2.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |